Prosecution Insights
Prosecution Insights
42 pending office actions • 23 art units • 40 examiners • 0 of 42 (0%) have an AI response strategy ready • 24 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 25 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 25 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (12%) |
| §103 only | 16 (38%) |
| §112 only | 3 (7%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 5 (12%) |
| Multi-statute (no §101) | 12 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LARA, CAROLINE MONSERRAT | 2 | 100.0% | +0.0% |
| JOHANSEN, PETER N. | 2 | 58.9% | +24.3% |
| MENDEZ MUNIZ, DYLAN JOHN | 1 | 78.3% | +29.4% |
| BRAM, STANLEY | 1 | — | — |
| DAUNER, JOSEPH G | 1 | 56.8% | +35.6% |
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
| HEASLEY, MEGHAN CHRISTINE | 1 | 76.6% | +34.8% |
| JACKSON III, WALTER | 1 | 100.0% | +0.0% |
| SITTON, JEHANNE SOUAYA | 1 | 53.0% | +48.0% |
| CORNELIUS, CLAIRE ADRIENNE | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18555584 | CULTURE OF TUMOR INFILTRATING LYMPHOCYTES FROM TUMOR DIGEST | LARA, CAROLINE MONSERRAT | 36d overdue |
| 18569178 | CANCER THERAPIES COMPRISING PEPTIDE LOADED CXCR3- AND CCR5-INDUCING DENDRITIC CELLS AND CHEMOKINE MODULATORY AGENTS | JACKSON III, WALTER | — |
| 18556744 | ENGINEERING BIOLOGICS TO HPV ONCOPROTEINS | CORNELIUS, CLAIRE ADRIENNE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17584547 | CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATORY DOMAINS | SINGH, ANOOP KUMAR | 59d overdue |
| 18030186 | HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS | LEE, HOI YAN NMN | 31d overdue |
| 18842179 | CULTURE OF TUMOR INFILTRATING LYMPHOCYTES FROM TUMOR DIGEST | LARA, CAROLINE MONSERRAT | 30d overdue |
| 18546302 | CUSTOMIZED CHIMERIC ANTIGEN RECEPTOR POLYPEPTIDES | GUSTILO, ESTELLA M | 24d overdue |
| 17606489 | ARTIFICIAL ANTIGEN PRESENTING CELLS COMPRISING LIGANDS FOR NKG2D FOR EXPANDING IMMUNE CELLS FOR IMMUNOTHERAPY | ZHU, JIANJIAN | 5d overdue |
| 18555582 | FUCOSYLATION AND IMMUNE MODULATION IN CANCER | MILLER, DALE R | 2d overdue |
| 18000312 | Dual EGFR-MUC1 Chimeric Antigen Receptor T Cells | HOPKINS, SAMANTHA LAKE | 20d |
| 17913033 | TAF1 INHIBITORS | PALENIK, JEFFREY T | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17622375 | A PEPTIDE-BASED SCREENING METHOD TO IDENTIFY NEOANTIGENS FOR USE WITH TUMOR INFILTRATING LYMPHOCYTES | JOHANSEN, PETER N. | 58d overdue |
| 16610279 | TARGETED CYTOKINE BLOCKADES FOR CAR-T THERAPY | JOHANSEN, PETER N. | 3d overdue |
| 18772456 | METHODS AND SYSTEMS FOR INTEGRATING HIGH-THROUGHPUT CELLULAR PROFILES USING CELL CYCLE STATES | MENDEZ MUNIZ, DYLAN JOHN | — |
| 18709722 | METHYLATION SIGNATURES IN CELL-FREE DNA FOR TUMOR CLASSIFICATION AND EARLY DETECTION | DAUNER, JOSEPH G | — |
| 18697835 | INHIBITORS OF ULK1 AND METHODS OF USE | CORNET, JEAN P | — |
| 18570899 | TRIAZINE INHIBITORS OF CYCLIN-DEPENDENT KINASES | HEASLEY, MEGHAN CHRISTINE | — |
| 18556748 | DIAGNOSTIC TO SUPPORT CLINICAL TRIAL MATCHING AND EXPLORATORY BIOMARKER ANALYSES IN CANCER PATIENTS | SITTON, JEHANNE SOUAYA | — |
| Art Unit | Apps |
|---|---|
| 1633 | 3 |
| 1638 | 3 |
| 1693 | 3 |
| 1644 | 3 |
| 1631 | 3 |
| 1682 | 2 |
| 1622 | 2 |
| 1646 | 2 |
| 1647 | 2 |
| 1691 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18842179 | CULTURE OF TUMOR INFILTRATING LYMPHOCYTES FROM TUMOR DIGEST | LARA, CAROLINE MONSERRAT | 1633 | §101§102§103§112Other | Non-Final OA | 30d overdue | Pending | Aug 28, 2024 |
| 18772456 | METHODS AND SYSTEMS FOR INTEGRATING HIGH-THROUGHPUT CELLULAR PROFILES USING CELL CYCLE STATES | MENDEZ MUNIZ, DYLAN JOHN | 2675 | §102§103 | Non-Final OA | — | Pending | Jul 15, 2024 |
| 18768434 | AURORA KINASE AND JANUS KINASE INHIBITORS FOR PREVENTION OF GRAFT VERSUS HOST DISEASE | BRAM, STANLEY | — | §103 | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18709722 | METHYLATION SIGNATURES IN CELL-FREE DNA FOR TUMOR CLASSIFICATION AND EARLY DETECTION | DAUNER, JOSEPH G | — | §101§102§112 | Non-Final OA | — | Pending | May 13, 2024 |
| 18697835 | INHIBITORS OF ULK1 AND METHODS OF USE | CORNET, JEAN P | 1628 | §103 | Non-Final OA | — | Pending | Apr 02, 2024 |
| 18570899 | TRIAZINE INHIBITORS OF CYCLIN-DEPENDENT KINASES | HEASLEY, MEGHAN CHRISTINE | 1626 | §103 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18569178 | CANCER THERAPIES COMPRISING PEPTIDE LOADED CXCR3- AND CCR5-INDUCING DENDRITIC CELLS AND CHEMOKINE MODULATORY AGENTS | JACKSON III, WALTER | 1638 | §103 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18556748 | DIAGNOSTIC TO SUPPORT CLINICAL TRIAL MATCHING AND EXPLORATORY BIOMARKER ANALYSES IN CANCER PATIENTS | SITTON, JEHANNE SOUAYA | 1682 | §101§102§112 | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18556744 | ENGINEERING BIOLOGICS TO HPV ONCOPROTEINS | CORNELIUS, CLAIRE ADRIENNE | 1672 | §112 | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18556241 | SMALL-MOLECULE INHIBITORS FOR BETA-CATENIN/BCELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | ELENISTE, PIERRE PAUL | 1622 | §102§103§112 | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18555584 | CULTURE OF TUMOR INFILTRATING LYMPHOCYTES FROM TUMOR DIGEST | LARA, CAROLINE MONSERRAT | 1633 | §112DP | Final Rejection | 36d overdue | Pending | Oct 16, 2023 |
| 18555582 | FUCOSYLATION AND IMMUNE MODULATION IN CANCER | MILLER, DALE R | 1693 | §102§103§112Other | Non-Final OA | 2d overdue | Pending | Oct 16, 2023 |
| 18280836 | COMPOSITIONS AND METHODS TO REDUCE THERAPEUTIC T CELL TOXICITY | JUEDES, AMY E | 1644 | §102§103§112 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18546302 | CUSTOMIZED CHIMERIC ANTIGEN RECEPTOR POLYPEPTIDES | GUSTILO, ESTELLA M | 1646 | §102§103§112 | Non-Final OA | 24d overdue | Pending | Aug 14, 2023 |
| 18262287 | BI-SPECIFIC CAR T CCELLS FOR B CELL MALIGNANCIES | METCALF, MATTHEW CURRAN | 1647 | §103Other | Non-Final OA | 28d | Pending | Jul 20, 2023 |
| 18139607 | Device, System, and Method for Intraoperative Quantification of Blood Loss | STRACHAN, KATE ELIZABETH | 3781 | §103 | Non-Final OA | 4d overdue | Pending | Apr 26, 2023 |
| 18030186 | HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS | LEE, HOI YAN NMN | 1693 | §101§102 | Non-Final OA | 31d overdue | Pending | Apr 04, 2023 |
| 18023261 | IMMUNE GENE SIGNATURES IN MUSCLE INVASIVE BLADDER CANCER | TURPIN, ZACHARY MARK | 1682 | DP | Final Rejection | — | Pending | Feb 24, 2023 |
| 18021847 | COMBINATION THERAPY COMPRISING HER-2-DC1 VACCINE, A PROBIOTIC, AND SEMAPHORIN | ARMATO JR, DENNIS IGNATIUS | 1651 | §103Other | Non-Final OA | 23d | Pending | Feb 17, 2023 |
| 18021845 | COMBINATION THERAPY COMPRISING HER-2-DC1 VACCINE AND A PROBIOTIC | BUTTICE, AUDREY L | 1647 | §103§112DP | Final Rejection | 119d overdue | Pending | Feb 17, 2023 |
| 18021320 | PYRIMIDINYL SULFONAMIDES AS INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §103Other | Non-Final OA | 18d overdue | Pending | Feb 14, 2023 |
| 18011338 | OLFACTORY RECEPTORS FOR USE AS TARGETS FOR ANTIGEN BINDING MOLECULES TO DETECT AND TREAT CANCER | GANGLE, BRIAN J | 1645 | §102§112 | Non-Final OA | 48d | Pending | Dec 19, 2022 |
| 18000312 | Dual EGFR-MUC1 Chimeric Antigen Receptor T Cells | HOPKINS, SAMANTHA LAKE | 1641 | §102§103§112Other | Non-Final OA | 20d | Pending | Nov 30, 2022 |
| 17913033 | TAF1 INHIBITORS | PALENIK, JEFFREY T | 1615 | §103§112 | Non-Final OA | 33d | Pending | Sep 20, 2022 |
| 17905131 | TUMOR-INFILTRATING LYMPHOCYTES WITH ENHANCED TUMOR REACTIVITY | ABUZEINEH, HANAN ISAM | 1633 | §103 | Non-Final OA | — | Pending | Aug 26, 2022 |
| 17757475 | Systems and Methods for Producing Efficacious Regulatory T Cells | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103 | Non-Final OA | — | Pending | Jun 16, 2022 |
| 17783937 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | KIM, TAEYOON | 1631 | §102§103§112 | Final Rejection | 33d | Pending | Jun 09, 2022 |
| 17782897 | CLINICAL DECISION SUPPORT FOR PERSONALIZED ADAPTIVE PROSTATE CANCER THERAPY | GROOMS, TIFFANY NICOLE | 1637 | §101§102§103 | Final Rejection | 33d | Pending | Jun 06, 2022 |
| 17756138 | AKT INHIBITORS FOR ENHANCING CHIMERIC T CELL PERSISTENCE | VIVLEMORE, TRACY ANN | 1638 | §112 | Non-Final OA | 44d overdue | Pending | May 18, 2022 |
| 17776760 | COMBINATION THERAPY WITH PROTEIN KINASE B ACTIVATION INHIBITOR TO TREAT CANCER | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §103 | Non-Final OA | 22d | Pending | May 13, 2022 |
| 17642809 | HER3 PULSED DC1 THERAPY | VAN BUREN, LAUREN K | 1638 | §103DP | Final Rejection | 229d overdue | Pending | Mar 14, 2022 |
| 17685892 | HISTONE DEACETYLASE AS A MODULATOR OF PDLI EXPRESSION AND ACTIVITY | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §112 | Non-Final OA | 117d overdue | Pending | Mar 03, 2022 |
| 17638363 | METHODS OF ENHANCING CAR T CELL THERAPY | BURKE, TIONNA M | 2178 | §103 | Final Rejection | — | Pending | Feb 25, 2022 |
| 17636532 | DIAGNOSTICS AND METHODS FOR PROGNOSING RESPONSE TO IMMUNOTHERAPY BASED ON THE METHYLATION STATUS OF IMMUNE SYNAPSE GENE SIGNATURE | LEWIS, PATRICK T | 1691 | §103 | Non-Final OA | 18d overdue | Pending | Feb 18, 2022 |
| 17635119 | ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING T REGULATORY CELLS | LUNDE, GRACE HENRY | 1641 | §103§112DP | Non-Final OA | 184d overdue | Pending | Feb 14, 2022 |
| 17584547 | CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATORY DOMAINS | SINGH, ANOOP KUMAR | 1632 | §103§112 | Final Rejection | 59d overdue | Pending | Jan 26, 2022 |
| 17626315 | ENGINEERING NOTCH LIGANDS TO ENHANCE THE ANTI-TUMOR ACTIVITY OF ADOPTIVELY TRANSFERRED T CELLS | DENT, ALANA HARRIS | 1643 | §102§103DP | Final Rejection | — | Pending | Jan 11, 2022 |
| 17622375 | A PEPTIDE-BASED SCREENING METHOD TO IDENTIFY NEOANTIGENS FOR USE WITH TUMOR INFILTRATING LYMPHOCYTES | JOHANSEN, PETER N. | 1644 | §103 | Non-Final OA | 58d overdue | Pending | Dec 23, 2021 |
| 17614936 | THERAPEUTIC T-CELLS WITH MODIFIED EXPRESSION OF T-BET, EOMES, AND c-MYB TRANSCRIPTION FACTORS | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103 | Non-Final OA | — | Pending | Nov 29, 2021 |
| 17606489 | ARTIFICIAL ANTIGEN PRESENTING CELLS COMPRISING LIGANDS FOR NKG2D FOR EXPANDING IMMUNE CELLS FOR IMMUNOTHERAPY | ZHU, JIANJIAN | 1631 | §102§103Other | Final Rejection | 5d overdue | Pending | Oct 26, 2021 |
| 17430331 | COMBINATION OF T-CELL THERAPY AND TARGETED THERAPY FOR TREATING THERAPY-RESISTANT MELANOMA WITH MUTATIONS IN THE BRAF GENE | FAUST, AMBER KATHLEEN | 1643 | §103§112 | Final Rejection | — | Pending | Aug 12, 2021 |
| 16610279 | TARGETED CYTOKINE BLOCKADES FOR CAR-T THERAPY | JOHANSEN, PETER N. | 1644 | §103 | Non-Final OA | 3d overdue | Pending | Nov 01, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial